Ricevi le ultime notizie sulle azioni Kamada con aggiornamenti su tendenze di mercato, dati finanziari e analisi di Benzinga. Rimani informato sulle performance di KMDA

Ultime notizie per

Kamada

Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, the Proprietary Products segment and the Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Kamada Ltd

Health Care

Press Releases

Kamada Announces Expansion of Plasma Collection Operations with the Opening of New Site in San Antonio, Texas

News

Dividends

General

Kamada Updates on Withholding Tax Procedures on Previously Announced Special Cash Dividend to Shareholders

Kamada Announces Launch of a Comprehensive Post-Marketing Research Program for CYTOGAM®

Kamada to Announce First Quarter 2025 Financial Results on May 14, 2025

Earnings

Kamada Reports Strong First Quarter 2025 Financial Results with Year Over Year Top Line Growth of 17% and a 54% Increase in Profitability

Kamada Confirms Continuous Global Business Operations and Products Availability Despite Recent Events in the Middle East

Kamada to Announce Second Quarter and First Half Ended June 30, 2025 Financial Results on August 13, 2025

Kamada Announces FDA Approval of its Plasma Collection Center in Houston, Texas

Kamada Reports Strong Second Quarter and First Half 2025 Financial Results with 11% Year-Over-Year 6-Month Top Line Growth and a 35% Increase in Profitability; Raises Full-Year Profitability Guidance

Kamada to Participate in Upcoming September Investor Conferences

KMDA

Amarin Corporation plc - American Depositary Shares

Amarin Corp

Annexon

Aura Biosciences

Benitec Biopharma

Candel Therapeutics

Cullinan Therapeutics, Inc. - Common Stock

Cullinan Therapeutics

Cellectis S.A. - American Depositary Shares

Cellectis

DBV Technologies S.A. - American Depositary Shares

DBV Technologies

DiaMedica Therapeutics Inc. - Common Stock

DiaMedica Therapeutics

Bright Minds Biosciences Inc. - common stock

Bright Minds Biosciences

Design Therapeutics

Editas Medicine

4D Molecular Therapeutics, Inc. - Common Stock

4D Molecular Therapeutics

Immuneering Corporation - Class A Common Stock

Immuneering

Invivyd

Jade Biosciences

Korro Bio

Lineage Cell Therapeutics, Inc. Common Stock

Lineage Cell Therapeutics

Larimar Therapeutics, Inc. - Common Stock

Larimar Therapeutics

Lexeo Therapeutics

Lyell Immunopharma

ProKidney Corp. - Class A Ordinary Shares

ProKidney

PureTech Health plc - American Depositary Shares

PureTech Health

Rocket Pharmaceuticals, Inc. - Common Stock

Rocket Pharmaceuticals

Replimune Group

Benchmark

HC Wainwright & Co.

Stifel

Screenshot 2025-06-10 at 5.36.48 PM

Kamada Q1 Results: Double-Digit Growth, Company Reiterates Guidance As It Hits Multiple Milestones Including Plasma Business Expansion

Screenshot 2025-06-05 at 5.39.34 PM

Biotech

Kamada Wants To Do More For Organ Transplant Patients, Increases Efforts To Build Awareness Of Its CMV Treatment CYTOGAM

Screenshot 2025-04-21 at 5.40.48 PM

Kamada Expects Third Plasma Collection Site To Support Its Hyper-Immune Plasma Needs And Add Up To $10M In Annual Revenue At Full Capacity

Screenshot 2025-04-15 at 5.37.39 PM

Kamada Is Bringing Relief To Those With Rare And Serious Conditions

Screenshot 2025-03-13 at 5.37.46 PM

Movers & Shakers

Kamada Announces Dividend After Record-Breaking Year, Anticipates Further Double-Digit Growth

Screenshot 2025-02-27 at 6.38.52 PM

TEVA

How Kamada (NASDAQ: KMDA) Is Transforming Its Strategic Focus Into Commercial Growth

Comments

Kamada Notizie sulle azioni

Notizie

Ultime notizie per

Le persone guardano anche

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO